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CASE REPORT
Alpha-fetoprotein (AFP) is the most commonly
used biomarker for surveillance of hepatocellu-
lar carcinoma (HCC), and HCC is the fifth most
common solid tumor in the world, with about
500,000 deaths each year.1 Since 1984, it has been
the leading cause of cancer death in Taiwan.2 The
major drawback of using AFP as a screening tool is
that AFP is normal in around one third of small
HCC (< 3 cm) patients.3 Because of its limited
sensitivity and specificity, some investigators do
not consider AFP to be useful for the surveillance
of HCC.4
Compared with HCC, the incidence of pan-
creas cancer is much lower. The most commonly
used biomarker for pancreatic cancer is CA19-9.
However, CA19-9 is not an ideal marker since its
sensitivity is only 87% and specificity only 86%
for pancreatic cancers when the upper normal
limit is set to 37 U/mL.5 AFP is rarely elevated in
patients with pancreatic cancer. Here, we report a
rare case of hepatitis B with progressive elevation
of AFP, which turned out to be pancreas acinar cell
carcinoma rather than HCC.
Case Report
A 47-year-old man was referred to our hospital
in January 2000 for evaluation of chronic hepatitis
B and elevated AFP (41 ng/mL; upper limit of nor-
mal, < 20 ng/mL), which were incidentally noted
on routine health check-up. He did not have any
symptoms. He had had acute hepatitis in child-
hood. Abdominal sonographic examination re-
vealed fatty liver without focal lesion. Abdominal
computed tomography (CT) done in November
2000 did not reveal any hepatic tumor. However,
unusual fatty sparing region in the pancreatic tail
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with nodular shape and poor enhancement was
noted. Pancreatic lipomatosis with focal fatty
sparing region or pancreatic lipomatosis with
pancreatic tumor was considered at that time.
However, his AFP level progressively elevated from
43 ng/mL to 388 ng/mL over the next 2 years.
Therefore, he was admitted.
Physical examination revealed a well nourished
man. His vital signs were normal: blood pressure,
124/66 mmHg; pulse rate, 80 beats/min; respira-
tory rate, 12/min. The abdomen was soft and non-
tender, and no palpable mass or organomegaly
were noted. Laboratory findings were: hemoglobin,
13.9 g/dL; hematocrit, 40.4%; white blood cell
count, 6.19 K/µL; serum total protein, 6.9 g/dL;
aspartate aminotransferase, 19 U/L (normal range
< 37 U/L); total bilirubin, 0.6 mg/dL; amylase,
40 U/L (normal range <220 U/L). Serum AFP level
was elevated to 463.69 ng/mL, while both serum
carcinoembryonic antigen (0.82 ng/mL; normal
range <5.0 ng/mL) and CA19-9 (7.88 U/mL, nor-
mal range < 37 U/mL) were within normal limits.
Abdominal CT showed diffuse fatty replace-
ment of the pancreas with a low density lesion
about 2 cm in diameter with peripheral enhance-
ment at the pancreatic tail (Figure 1). There was no
focal lesion in the liver. The differential diagnosis
of the pancreatic tumor included pancreatic ade-
nocarcinoma and non-functioning pancreatic
endocrine tumor. Pancreatic adenocarcinoma was
most likely since there was central necrotic part
in the tumor, which is often the case in pancreatic
adenocarcinoma.6 The richness of vascularity in the
non-functioning pancreatic endocrine tumor made
central necrosis less probable.7 Angiography of
celiac trunk, splenic artery, common hepatic artery,
gastroduodenal artery and superior mesentery
artery failed to demonstrate tumor stains in the
pancreas.
The patient underwent elective distal pancre-
atectomy and splenectomy in May 2002. The re-
sected specimen showed a 2-cm well-defined and
encapsulated yellowish elastic tumor at the pan-
creatic tail. Histologic resection showed an encap-
sulated lobulated tumor with thin fibrous septae
and uniform tumor cells arranged in a papillary,
glandular, trabecular or cystic pattern. Immuno-
histochemical studies showed diffuse positive cy-
tokeratin stains and presence of zymogen granules
manifested by scattered DPAS (diastase-resistant
periodic acid Schiff) and α1-antitrypsin stains
(Figure 2). Thus, acinar cell carcinoma of the pan-
creas was diagnosed.
There was no evidence of distant metastasis at
the time of diagnosis, so the patient did not receive
chemotherapy after surgery. The level of AFP de-
clined rapidly within 1 week to 110.66 ng/mL
and returned to normal range within 3 months.
No cancer recurrence was noted after a 3-year 
follow-up.
Discussion
Although AFP is usually a screening marker for
HCC, AFP is not specific for HCC. In addition to
HCC, AFP can also be elevated in germ cell tumors
and, much more rarely, in pancreatic, gastric, colon
and lung cancers.8
Acinar cell carcinoma is a pancreatic epithelial
tumor that can occasionally have a neuroendocrine
component. It is an uncommon tumor, represent-
ing only 1–2% of all exocrine tumors of the pan-
creas.9 Clinical symptoms are nonspecific, jaundice
is infrequent, and about 16% of patients may have
complications related to elevated serum lipase
Figure 1. Abdominal computed tomography of the pancreas
shows a well circumscribed pancreatic tumor (arrow) with
central necrosis and hypervascular rim. The splenic vein is
not involved, and diffuse fatty change of the pancreas is
not found (dot tailed arrow).
(e.g. arthralgia, subcutaneous fat necrosis). Once
the diagnosis is made, surgical resection remains
the only chance of cure. However, only 15% of
patients are candidates for curative surgery at the
time of diagnosis. The reported prognosis of aci-
nar cell carcinoma of the pancreas is relatively
poor; mean survival was 18 months with 1- and
3-year survivals of 57% and 26%, respectively, in
a series review of 28 cases. A large series showed
5-year survival rates of 10.5–25% and median
survival between 10.5 and 20 months for patients
who underwent resective surgery.10–12 About 50%
of patients had metastatic disease at presentation
and an additional 23% subsequently developed
metastases, which were usually restricted to the
regional lymph nodes and liver.13
Typical CT findings of acinar cell carcinoma
of the pancreas include a well-defined hypodense
tumor, and larger tumors could have an enhancing
thin capsule. Multiple small- and medium-sized 
irregular low-density areas might suggest necrosis.14
With these characteristics, acinar cell carcinoma
AFP-producing pancreatic cancer
J Formos Med Assoc | 2007 • Vol 106 • No 8 671
A B
DC
E Figure 2. (A) Immunohistochemical study shows an en-
capsulated lobulated tumor with fibrous dense stromal
septae and uniform tumor cells arranged in papillary, glandu-
lar, trabecular or cystic patterns (hematoxylin & eosin,40×).
(B) Large areas of myxoid or hyalinized stroma are present
(hematoxylin & eosin, 100×). (C) Cytokeratin stain shows
diffuse positivity. (D) DPAS (diastase-resistant periodic acid
Schiff) stain shows scattered positivity. (E) α1-antitrypsin
stain shows scattered positivity.
can be distinguished from locally invasive com-
mon adenocarcinoma of the pancreas, but differ-
entiation from other less common pancreatic
tumors remains difficult.15 The tumor in our 
patient had peripheral enhancement on CT, which
was suggestive of encapsulation and thus in favor
of acinar cell carcinoma. The presence of diffuse
fatty change of the pancreas, which is common in
patients with lipomatosis due to cystic fibrosis, is
uncommon in patients with pancreatic acinar
cell carcinoma and young adults. However, it was
relatively difficult to differentiate the lesion from
pancreatic adenocarcinoma.
Acinar cell carcinomas of the pancreas can be
stained by several immunohistochemical markers.
In a series study of 28 cases, more than half (61%)
showed positivity for α1-antitrypsin. Keratin (AE1/
AE3) staining was present in 77% and was occa-
sionally quite intense, but AFP was positive in only
6% of the cases.11 However, no studies have been
conducted to investigate the relationship between
the presence of different immunohistochemical
markers and disease prognosis. Though there are
several immunohistochemical markers for acinar
cell carcinoma of the pancreas, none has been
proven to be of value for early detection. Our 
patient had no clinical symptoms or any somatic
discomfort. His pancreatic tumor could have been
missed if there had been no regular follow-up for
his hepatitis B by AFP and abdominal ultrasound.
Regarding reported cases with AFP-producing pan-
creatic acinar cell carcinoma, more than 70% of
cases eventually developed distant metastasis
within 2 years of diagnosis.16,17 Our patient seemed
to have excellent prognosis in comparison.
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